// App-Quantinova.ai

e17553 : Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).

Researchers

Presenter

  • Ignacio Matos

Principal Investigators

  • Enrique Grande

  • Javier Martinez Trufero

  • Jose Manuel Trigo

  • Carlos Lopez

  • Jose Luis Manzano

  • Oscar Reig

  • Cristina Alvarez

  • Miguel Beltran

  • Manuel Duran

  • Javier Aller

  • Lara Iglesias

  • Sara Arevalo

  • Aranzazu Manzano

  • Ricard Mesia

  • Juan J Reina

  • Juan Manuel Sepulveda

  • JA Virizuela

  • Jaume Capdevila

Medical Centers

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Medical Oncology Department. Hospital Universitario La Paz, Madrid, Spain

  • Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain

  • IBIMA-Hospital Regional Universitario y Virgen de la Victoria, Malaga, Spain

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology. Hospital Clinic Barcelona, Barcelona, Spain

  • Hospital La Paz, Madrid, Spain

  • Institut Catala d'Oncologia Hospital Universitari Josep Trueta, Girona, Spain

  • Rey Juan Carlos University Hospital, Madrid, Spain

  • Puerta de Hierro Majadahonda University Hospital, Madrid, Spain

  • Medical Oncology Dpt, 12 de Octubre Hospital, Madrid, Spain

  • Hospital de Donostia, Guipuzcoa, Spain

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

  • Medical Oncology Department, Institut Catala d'Oncologia (ICO) L'Hospitalet, University of Barcelona, Barcelona, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Medical Oncology Department. Hospital Universitario Virgen del Rocio, Seville, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Thyroid Cancer

Biomarkers

  • High affinity nerve growth factor receptor

  • Disseminated tumor cells

Drug/Treatment

  • Cabozantinib

  • Lenvatinib

  • Vandetanib

  • Pazopanib

  • Sorafenib

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved